Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Equity Average (2016 - 2025)

Altimmune (ALT) has disclosed Equity Average for 15 consecutive years, with $173.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 21.36% to $173.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $173.5 million, a 21.36% increase, with the full-year FY2024 number at $158.8 million, down 16.29% from a year prior.
  • Equity Average was $173.5 million for Q3 2025 at Altimmune, up from $151.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $243.9 million in Q2 2021 to a low of $128.4 million in Q4 2024.
  • A 5-year average of $180.9 million and a median of $176.5 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 440.3% in 2021, then fell 27.62% in 2025.
  • Altimmune's Equity Average stood at $204.2 million in 2021, then dropped by 4.43% to $195.2 million in 2022, then decreased by 11.74% to $172.2 million in 2023, then decreased by 25.43% to $128.4 million in 2024, then surged by 35.07% to $173.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Equity Average are $173.5 million (Q3 2025), $151.8 million (Q2 2025), and $132.8 million (Q1 2025).